Venture
Castle Creek Biosciences, Inc.
Latest Form D 2025-02-25- CIK 1756702
- State NJ
- Biotechnology
- 6 Form D offerings since 2018-10-24
- Total sold
- $840M
- across 6 offerings
- Rounds
- 6
- Form D offerings since 2018-10-24
- Latest round
- $75M
- 2025-02-25 · 021-539194
- Investors
- 30
- on the latest round
Connected
named in its Form D filingsRound timeline
amount sold · by first filed2025-02-25 · $75M
- 2018-10-24$561M021-324223
- 2020-01-21$54.6M021-358609
- 2021-07-09$25M021-405683
- 2022-02-03$11.9M021-432178
- 2022-05-02$113M021-444058
- 2025-02-25$75M021-539194
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($561M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-539194 | First filed2025-02-25 | Latest2025-02-25 | Sought$75M | Sold$75M | Investors30 | Exemptions506(b) |
| 021-444058 | First filed2022-05-02 | Latest2022-05-02 | Sought$113M | Sold$113M | Investors54 | Exemptions506(b) |
| 021-432178 | First filed2022-02-03 | Latest2022-02-03 | Sought$11.9M | Sold$11.9M | Investors6 | Exemptions506(b) |
| 021-405683 | First filed2021-07-09 | Latest2021-07-09 | Sought$25M | Sold$25M | Investors36 | Exemptions506(b) |
| 021-358609 | First filed2020-01-21 | Latest2020-01-21 | Sought$54.6M | Sold$54.6M | Investors12 | Exemptions506(b) |
| 021-324223 | First filed2018-10-24 | Latest2018-10-24 | Sought$561M | Sold$561M | Investors19 | Exemptions506(b) |
Who backs Castle Creek Biosciences, Inc., inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2025-02-25
| Name | Relationship |
|---|---|
| Matthew Gantz | RelationshipExecutive Officer, Director |
| Jude Sullivan | RelationshipExecutive Officer |
| Darien Parhad | RelationshipExecutive Officer |
| Matthew Crabtree | RelationshipDirector |
| Patrick Morris | RelationshipDirector |
| Jeffrey Aronin | RelationshipDirector |
| Antonio Gracias | RelationshipDirector |
| David Brill | RelationshipDirector |
Sales compensation
Named in Item 12 of its Form D filings
| Recipient | CRD | Broker-dealer | Offerings |
|---|---|---|---|
| Paragon Health Capital, LLC | CRD300729 | Broker-dealer— | Offerings5 |
| Octagon Capital Group, LLC | CRD173341 | Broker-dealer— | Offerings1 |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- New Jersey (NJ)
- Exemptions
- Rule 506(b)
- First filed
- 2018-10-24
- Latest filing
- 2025-02-25
Who backs Castle Creek Biosciences, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗